Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes (SCORPIO)

项目总结/摘要 季节性和流行性结膜炎（红眼病）感染具有高度传染性， 在美国和世界范围内的经济负担。可能会出现长期视力障碍。在儿童中， 结膜炎可能预示着更严重的系统性并发症，导致住院甚至死亡。 有效遏制疫情的机制目前面临的挑战是缺乏跟踪和报告， 获得用于分析的样本采集，有限的诊断测试能力，以及不完整的 了解相关病原体。该项目的总体目标是将国际联合收割机 在基因组技术方面的合作努力和进展，以确定病原体，全球趋势，病原体 进化和免疫反应参与结膜炎的流行病学。我们建议加强 了解结膜炎的发病机制，目的如下。第一个目标将决定如何 腺病毒基因组类型在一个区域内和跨区域变化。第二个目标是确定新兴的 季节性和流行性结膜炎的原因。最后，我们将识别局部免疫应答特征 感染性结膜炎的儿童和成人。我们预期结膜基因表达谱将 准确预测疾病相关并发症。这个项目有可能改善公众健康 监测，指导有针对性的干预措施，改善疫苗开发，并提高现有的诊断 这是治疗结膜炎的最佳范例，以减轻全球的经济和眼部健康负担。

PROJECT SUMMARY/ABSTRACT Seasonal and epidemic conjunctivitis (pink eye) infections are highly contagious and impose significant economic burden in the United States and worldwide. Long-term visual impairment can occur. In children, conjunctivitis may herald more serious systemic complications leading to hospitalizations and even deaths. Current challenges to effective mechanisms to curtail outbreaks are the lack of tracking and reporting, poor access to sample collection for analysis, limited diagnostic testing capabilities, and an incomplete understanding of the pathogens involved. The overall goal of this project is to combine international collaboration efforts and advances in genomic technologies to identify pathogens, global trends, pathogen evolution, and the immune responses involved in the epidemiology of conjunctivitis. We propose to enhance the understanding of the pathogenesis of conjunctivitis with the following aims. The first aim will determine how adenovirus genome types vary within a region and across regions. The second aim will identify emerging causes of seasonal and epidemic conjunctivitis. Finally, we will identify the local immune response signatures of children and adults with infectious conjunctivitis. We expect that conjunctival gene expression profiles will accurately predict disease associated complications. This project has the potential to improve public health surveillance, guide targeted interventions, improve vaccine development, and elevate existing diagnostic paradigms for conjunctivitis, to reduce both the financial and ocular health burden worldwide.